Compare · MTVA vs NVO
MTVA vs NVO
Side-by-side comparison of MetaVia Inc. (MTVA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MTVA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 18884.0x MTVA ($10.1M).
- Over the past year, MTVA is down 74.2% and NVO is down 44.3% - NVO leads by 29.9 points.
- MTVA has been more active in the news (19 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 2 for MTVA).
- Company
- MetaVia Inc.
- Novo Nordisk A/S
- Price
- $2.13+10.94%
- $43.80+2.36%
- Market cap
- $10.1M
- $191.15B
- 1M return
- +119.59%
- -6.68%
- 1Y return
- -74.18%
- -44.30%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- News (4w)
- 19
- 8
- Recent ratings
- 2
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MTVA
- Presenting on Emerging Growth Conference 93 Day 2 on June 11; Register to live stream
- Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream
- BioStem Technologies Announces Appointment of Three New Members to its Board of Directors
- Director Tursi James Patrick was granted 17,186 shares, increasing direct ownership by 508% to 20,568 units (SEC Form 4)
- Director Strickland D Gordon was granted 17,186 shares, increasing direct ownership by 414% to 21,339 units (SEC Form 4)
- Director Salsbury Michael was granted 17,186 shares, increasing direct ownership by 414% to 21,338 units (SEC Form 4)
- Director Groves Jason L was granted 17,186 shares, increasing direct ownership by 414% to 21,338 units (SEC Form 4)
- Director Koven Andrew I was granted 17,186 shares, increasing direct ownership by 414% to 21,339 units (SEC Form 4)
- Director Glickman Mark A was granted 17,186 shares, increasing direct ownership by 499% to 20,629 units (SEC Form 4)
- SEC Form S-8 filed by MetaVia Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care